Newsroom

Strive to Deliver Breakthroughs

  1. June 17, 2021

    Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – June 17, 2021   Harbour BioMed (“HBM”, HKEX: 02142) today announced the dosing of the f...

    View more
  2. June 16, 2021

    Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment

      Cambridge, MA, Rotterdam, NL, Suzhou CN – June 16, 2021   Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-y...

    View more
  3. June 08, 2021

    HabourBioMed will announce a bispecific antibody at Antibody Engineering & Therapeutics Conference

    HabourBioMed will announce a bispecific antibody at Antibody Engineering & Therapeutics (AET)Conference  (June 8-10, 2021). This anti...

    View more
  4. June 02, 2021

    Capital Group increased its stake in Harbour BioMed to 6.1%

    CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands -  June 2, 2021 According to public information, on May 31, the C...

    View more
  5. May 11, 2021

    Harbour BioMed Announces Dosing of First Patient in Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody

    CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands -  May 11, 2021   Harbour BioMed (“HBM”, HKEX: ...

    View more
  6. April 13, 2021

    Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting

    CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands -  April 13, 2021    Harbour BioMed ("HBM"; ...

    View more
  7. March 30, 2021

    Harbour BioMed Reports Full Year 2020 Financial Results and Provides Corporate Update

    CAMBRIDGE, Mass., SUZHOU, China, Rotterdam, Netherlands - March 30, 2021   HBM Holdings Limited (“Harbour BioMed”, “HBM” or ...

    View more
  8. March 23, 2021

    Harbour BioMed Appoints Mai-Jing Liao, PhD, as Chief Commercial Officer

    Since its establishment, Harbour BioMed (HBM) continues to grow leaps and bounds with its innovative technology and differentiated R&D pipeline that keeps ...

    View more
  9. March 22, 2021

    Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China

    Cambridge, MA, Rotterdam, NL, Shanghai, CN, Suzhou, CN – March 22, 2021   Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the...

    View more
  10. March 12, 2021

    Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial

    Cambridge, MA, Rotterdam, NL, Shanghai, CN, Suzhou, CN – March 12, 2021   Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the...

    View more